NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PA-18-821 from the NIH Guide for Grants and Contracts. The purpose of the Administrative Supplements for Collaborative Activities to Promote Cachexia Research is to support collaborative, multidisciplinary basic and translational research that addresses an important question in cancer cachexia and to expand the cadre of investigators experienced in cancer cachexia study design, model systems and data interpretation. These supplement applications must propose a collaboration between cancer researchers and researchers with documented expertise in cachexia research. The parent grant for the supplement must have an NCI primary assignment. Overall, the long-term goal of this supplement program is to encourage a focused examination of the biology of cancer cachexia and its effect on organs and systems beyond the tumor site(s). Applicants are strongly encouraged to discuss potential requests with the NCI scientific contacts listed below.
Funding Opportunity RFA-AG-19-008 from the NIH Guide for Grants and Contracts. This FOA invites applications from qualified institutions to create a Roybal Center Coordinating Center (CC), serving the needs of the Roybal Centers for Translational Research on Aging program as well as the Roybal Centers for Translational Research on Dementia Care Provider Support program. The Roybal Coordinating Center will serve as a hub for the Roybal Center grant program. Roybal Center programs conduct translational in the behavioral and social sciences of aging, structured in accordance with the NIH Stage Model. Roybal Center program resources are intended for pilot and preliminary translational, multi-directional research at Stages 0 through IV of the behavioral intervention development pipeline with the goal of creating principle-driven interventions that improve the lives of mid-life and older people and the capacity of institutions to adapt to societal aging. The Roybal Coordinating Center will facilitate and coordinate trans-Roybal activities. The Center will work closely with the NIA Program Officer and, in coordination with all Roybal sites, will be responsive to requests generated by key Roybal site personnel, NIA, NIH, the scientific community, and the general public.
Funding Opportunity RFA-AG-19-007 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Edward R. Roybal Centers for translational intervention development research for Alzheimers Disease and Alzheimers Disease related dementias care provider support. The purpose of the Roybal Centers is to develop behavioral interventions that improve the health, well-being and/or capacity of individuals and/or systems that provide care to persons with AD-ADRD. Roybal Centers will conduct Stage 0 through IV pilot studies in accordance with the multidirectional, translational NIH Stage Model, to produce potent and implementable principle-driven behavioral interventions.
Funding Opportunity RFA-AG-19-006 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits Edward R. Roybal Centers for Translation Research in the Behavioral and Social Sciences of Aging. The purpose of the Roybal Centers is to develop behavioral interventions that improve the health and well-being of people as they are aging and the capacity of institutions to adapt to societal aging. Roybal Centers will conduct Stage 0 through IV pilot studies in accordance with the multidirectional, translational NIH Stage Model, to produce potent and implementable principle-driven behavioral interventions.
Funding Opportunity PAR-18-820 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, mechanisms of drug action, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies, or discovery activities such as high throughput screening and hit optimization.
Funding Opportunity PAR-18-822 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative clinical and preclinical/non-clinical research to improve our understanding of disease mechanisms in tuberculosis meningitis (TBM) and to improve therapy in the presence or absence of human immunodeficiency virus (HIV) co-infection.
Funding Opportunity PA-18-819 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages the translation of technologies for brain or behavioral research from academic and other non-small business research sectors to the marketplace. Encouraged from Small Business Concerns (SBCs) are Small Business Innovation Research (SBIR) grant applications that propose to further develop, make more robust, and make more user-friendly such technologies in preparation for commercial dissemination. It is expected that this activity will require partnerships and close collaboration between the original developers of these technologies and SBCs, which may be accomplished in any of a number of ways, including the use of multiple program directors/principal investigators.
Funding Opportunity PA-18-818 from the NIH Guide for Grants and Contracts. The reproducibility and comparability of research on dietary supplements is enhanced by rigorous analytical characterization of key experimental materials and the publication of validated analytical methods that accurately and precisely characterized and quantify constituents in dietary supplement ingredients and products. This FOA builds on existing NIH awards to support the performance and publication of formal single-laboratory validation studies of quantitative analytical methods. The methods proposed for validation must be used to identify and quantify dietary supplement-relevant chemical constituents (i.e., active or marker chemical compounds, adulterants, contaminants) or their metabolites in experimental reagents, raw materials, and/or clinical specimens (for example urine or plasma samples). Methods must have been developed or utilized in fulfillment of the active parent grants specific aims. Candidate constituents for quantitative method validation studies include (but are not limited to): phytochemicals, nutrients, and potentially deleterious substances such as pesticides and mycotoxins. Multi-laboratory validation studies will not be supported through this FOA.
Notice NOT-HL-18-631 from the NIH Guide for Grants and Contracts
Notice NOT-DE-18-019 from the NIH Guide for Grants and Contracts
Notice NOT-EB-18-018 from the NIH Guide for Grants and Contracts
Notice NOT-OD-18-185 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-18-817 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) announces the availability of administrative supplements to support research in which the supplemental funding would investigate the role of dietary supplements and/or their ingredients in health maintenance and disease prevention. Parent awards need not be focused on dietary supplements; this FOA may provide support to include dietary supplements within the scope of relevant research projects. Research interests of ODS are not limited to specific health conditions, organ systems or population groups. ODS supports all types of research, including pre-clinical, clinical, behavioral, and epidemiological. Additionally, ODS supports research and training programs that build future research capacity for studying the role of dietary supplements in health and disease prevention. Primary consideration for support will be given to applications that stimulate dietary supplement research where it is lacking or lagging, clarify gaps, opportunities and balance between benefits and risks where data are in conflict, target special population groups where additional science on dietary supplements is needed, and focus on the use of dietary supplements in improving or maintaining health and reducing the risk of chronic disease. This FOA will not support new clinical trials.
Funding Opportunity PA-18-815 from the NIH Guide for Grants and Contracts. Fetal bovine serum (FBS) is the most widely used growth supplement for cell culture because it cost-effectively supports the survival and growth of many cell lines. Although serum is an effective growth promotor, it is highly variable in its composition, activity, and physiological effects on cells. This variability introduces inconsistencies into cell culture research. This Funding Opportunity Announcement (FOA) will support SBIR projects to develop novel, reliable, and cost-effective tools that will make it easier for researchers to standardize or replace serum in cell culture.
Funding Opportunity PA-18-816 from the NIH Guide for Grants and Contracts. Fetal bovine serum (FBS) is the most widely used growth supplement for cell culture because it cost-effectively supports the survival and growth of many cell lines. Although serum is an effective growth promotor, it is highly variable in its composition, activity, and physiological effects on cells. This variability introduces inconsistencies into cell culture research. This Funding Opportunity Announcement (FOA) will support STTR projects to develop novel, reliable, and cost-effective tools that will make it easier for researchers to standardize or replace serum in cell culture.
Notice NOT-MD-18-006 from the NIH Guide for Grants and Contracts
Notice NOT-AA-18-010 from the NIH Guide for Grants and Contracts
Notice NOT-OD-18-174 from the NIH Guide for Grants and Contracts
Notice NOT-OD-18-187 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-18-813 from the NIH Guide for Grants and Contracts. The purpose of the NIH BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00) program is to increase workforce diversity in the neuroscience workforce and maintain a strong cohort of new and talented, NIH-supported, independent investigators by enhancing the pool of individuals from nationally underrepresented groups in BRAIN Initiative research areas. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (FOA #).